[2021] Global Herceptin Biosimilar Market to Surpass US$ 5.8 Billion by 2027, At a CAGR of 24.5 % | Coherent Market Insights

SEATTLE, May 04, 2021, (PHARMIWEB) —

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.

Key players are focusing on product approvals and launches for treatment of breast cancer and gastric cancer is expected to boost the growth of Global herceptin biosimilar market. For instance, Ogivri, a trastuzumab biosimilar developed by Mylan L.V. and Biocon Limited, was approved by the US Food and Drug Administration in 2019. Ogiviri is a drug that is used to treat patients with HER2-positive breast and gastric cancer.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4258

Moreover, in March 2020, Herzuma, a trastuzumab biosimilar developed by Celltrion Inc. and Teva Pharmaceutical Industries Ltd, was approved by the US Food and Drug Administration for the treatment of HER2-positive breast and gastric cancers.

Key companies focusing on product launches to strengthen their positioning in market is expected to boost the growth of Global herceptin biosimilar market.  For instance, the biosimilar trastuzumab (Zercepac) was introduced by Accord Healthcare Ltd in September 2020 for the treatment of patients with HER2-positive early breast cancer, previously untreated HER2-positive metastatic gastric cancer, and HER2-positive metastatic breast cancer. Zercepac will be available in a 150mg single dose vial and has been authorised by the European Commission in Europe.

Covid-19 Impact:

The COVID-19 pandemic has had a huge impact on every industry around the world, and it is predicted to have the following effects on the global herceptin biosimilar market:

Since the COVID-19 epidemic is impacting oncology care practises, government regulatory bodies have placed in place several guidelines to help slow the spread of COVID-19 infection. In a study released in July 2020, the US National Library of Medicine proposed recommendations for healthcare practitioners and clinical technicians to adopt while conducting oncology treatments. The following are some of the most relevant guidelines:

• To avoid the risk of spreading coronavirus infection, all oncology diagnostic procedures should be divided into urgent and non-urgent categories, and if urgent, a prescribed diagnostic plan should be properly developed.
• In the case of breast cancer patients, all surgical procedures and chemotherapy regimens should be planned based on their seriousness, which is classified as urgent priority, surgery within two weeks, high priority, surgery within four weeks, medium priority, surgery within eight weeks, low priority, surgery after eight weeks required.
• All oncology diagnostic procedures should be divided into two categories: urgent and non-urgent, with the latter requiring a well-defined diagnostic strategy to prevent coronavirus infection from spreading.
• All surgical procedures and chemotherapy regimens for breast cancer patients should be scheduled according to their severity, which is rated as urgent priority, surgery within two weeks, high priority, surgery within four weeks, medium priority, surgery within eight weeks, low priority, surgery after eight weeks needed.

Key players operating in the global herceptin biosimilar market are Amgen Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc ., Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/4258

Detailed Segmentation:

By Indication:

• • Breast Cancer
  • Gastric Cancer
  • Others

By Distribution Channel :

• • Hospitals
  • Oncology Centers
  • Others

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/herceptin-biosimilar-market-3522

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com